InterveXion Therapeutics is a drug discovery and development company focused on antibody-based therapies for treating human disease. We are developing monoclonal antibodies to treat substance abuse from PCP and methamphetamine. Abuse of these stimulants is increasing and no specific therapies are currently available for treatment.

InterveXion is developing PCP-mAb for the treatment of PCP abuse and METH-mAb for the treatment of methamphetamine abuse. These therapies are monoclonal antibodies that can "absorb" these toxins in the bloodstream to reduce the acute effects of overdose and can also be used in the chronic setting to help abusers overcome their dependency.

Our team has successfully developed business and regulatory strategies for the clinical delivery of new medicines, new biologics and "follow-on" biologics. We have also designed, constructed and operated cGMP compliant biologics manufacturing facilities.